Scientists at the University of Virginia School of Medicine have corrected the genetic mutation behind a severe inherited epilepsy in laboratory mice, using a technique called base editing that rewrites a single letter of DNA rather than cutting and replacing whole stretches of the genome. The team, led by Manoj Patel, PhD, of UVA's Department of Anesthesiology and the UVA Brain Institute, targeted SCN8A developmental and epileptic encephalopathy, or DEE - a condition marked by seizures, learning disabilities, movement problems and, in some cases, sudden death.
The biology of the disease explains why it is so hard to treat. A mutation in the SCN8A gene lets too much sodium flow into brain neurons, leaving those cells chronically overexcited. The result is seizures that frequently resist standard medications, along with physical and cognitive developmental delays. SCN8A-related epilepsy is estimated to affect about 1 in 56,000 births and roughly 1% of all epilepsies, though many specialists suspect it is underdiagnosed.
What distinguishes this work from conventional epilepsy drugs is where it intervenes. As Patel put it, treatments have historically addressed only the downstream effects of genetic mutations, while base editing makes it possible to correct the mutation itself. He argues the approach could apply well beyond epilepsy, to a range of diseases caused by single-gene errors, with real potential to change patients' quality of life.
The findings come from mice, not people, and that gap matters: correcting a mutation in a mouse brain is a very different proposition from delivering a gene editor safely and precisely into a child's nervous system. Still, for families facing a diagnosis with few effective drug options, a strategy aimed at the root cause rather than the symptoms is a meaningful shift in direction.